Scholarlink

Objective <p>This study aims to assess the comparative clinical effectiveness of the 3-chymotrypsin-like protease (3CLpro) inhibitors simnotrelvir-ritonavir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China.</p> Methods <p>The retrospective analysis of data from adult hospitalized patients with COVID-19 treated with either simnotrelvir-ritonavir or nirmatrelvir-ritonavir as antiviral treatment strategies will be conducted to determine any differences in clinical outcomes between the two drugs.</p> Results <p>This study involved a total of 585 participants, with 264 in the simnotrelvir group and 321 in the nirmatrelvir group. Following propensity score matching, there were 186 individuals in each group. There was no statistically significant difference in the cumulative risk of the composite disease progression, all-cause death, and respiratory support at 28&#xa0;days following initiation of drug exposure between the two groups (<i>p</i> &gt; 0.05). However, the simnotrelvir group exhibited more cases of clinical improvement compared to the nirmatrelvir group (33.602 events per 1000 person-days vs. 30.913 events per 1000 person-days), with a better cumulative incidence in the simnotrelvir group (<i>p</i> &lt; 0.05). The multivariate Cox regression analysis revealed that non-severe COVID-19 (HR 0.630, 95% CI 0.496–0.801; <i>p</i> &lt; 0.001), lower C-reactive protein (CRP) levels (HR 0.993, 95% CI 0.990–0.997; <i>p</i> &lt; 0.001), and treatment with simnotrelvir-ritonavir (HR 1.395, 95% CI 1.118–1.741; <i>p</i> = 0.003) were independently associated with a higher likelihood of clinical improvement.</p> Conclusion <p>This study illustrated that both simnotrelvir-ritonavir and nirmatrelvir-ritonavir exhibited similar effectiveness in reducing the incidence of composite disease progression, all-cause death, and the need for respiratory support amidst the real-world outbreak of the omicron VOC in China. Furthermore, simnotrelvir-ritonavir was found to be more favorable in enhancing the rate of clinical improvement in COVID-19 hospitalized patients, suggesting its potential clinical effectiveness against the disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Chuntao Li,
  • Qingzhao Cheng,
  • Ying Chen,
  • Ling Liu,
  • Dajin Liu,
  • Jiaqiang Zhang,
  • Zehua Liao,
  • Yaling Xiang,
  • Jinbiao Zhou,
  • Keke Liao,
  • Yandi Su,
  • Xuemei Zhang,
  • Jiashu Li,
  • Yuping Zhao,
  • Yue Yang,
  • Jianqing Zhang,
  • Long Yang

摘要

Objective

This study aims to assess the comparative clinical effectiveness of the 3-chymotrypsin-like protease (3CLpro) inhibitors simnotrelvir-ritonavir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China.

Methods

The retrospective analysis of data from adult hospitalized patients with COVID-19 treated with either simnotrelvir-ritonavir or nirmatrelvir-ritonavir as antiviral treatment strategies will be conducted to determine any differences in clinical outcomes between the two drugs.

Results

This study involved a total of 585 participants, with 264 in the simnotrelvir group and 321 in the nirmatrelvir group. Following propensity score matching, there were 186 individuals in each group. There was no statistically significant difference in the cumulative risk of the composite disease progression, all-cause death, and respiratory support at 28 days following initiation of drug exposure between the two groups (p > 0.05). However, the simnotrelvir group exhibited more cases of clinical improvement compared to the nirmatrelvir group (33.602 events per 1000 person-days vs. 30.913 events per 1000 person-days), with a better cumulative incidence in the simnotrelvir group (p < 0.05). The multivariate Cox regression analysis revealed that non-severe COVID-19 (HR 0.630, 95% CI 0.496–0.801; p < 0.001), lower C-reactive protein (CRP) levels (HR 0.993, 95% CI 0.990–0.997; p < 0.001), and treatment with simnotrelvir-ritonavir (HR 1.395, 95% CI 1.118–1.741; p = 0.003) were independently associated with a higher likelihood of clinical improvement.

Conclusion

This study illustrated that both simnotrelvir-ritonavir and nirmatrelvir-ritonavir exhibited similar effectiveness in reducing the incidence of composite disease progression, all-cause death, and the need for respiratory support amidst the real-world outbreak of the omicron VOC in China. Furthermore, simnotrelvir-ritonavir was found to be more favorable in enhancing the rate of clinical improvement in COVID-19 hospitalized patients, suggesting its potential clinical effectiveness against the disease.